Overview

A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Status:
RECRUITING

Trial end date:
2032-06-15

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

Phase:

PHASE2

Details

Lead Sponsor:

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Treatments:

Cyclophosphamide
fludarabine